Joanne Wuensch

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential. Dow’s Performance In 2024 The...

The Cleveland County District Court in Oklahoma ordered Johnson & Johnson (NYSE: JNJ) and its Janssen unit to pay $572 million to settle a lawsuit relating to their opioid drugs. The Analysts Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with...

Large-cap medtech company Medtronic PLC (NYSE: MDT) reported strong first-quarter results Tuesday, sending its shares to a 52-week high. The Analysts Wells Fargo Securities analyst Larry Biegelsen maintained an Outperform rating on Medtronic and $120 price target. BMO Capital Markets...

With Johnson & Johnson (NYSE: JNJ) facing off against the state of Oklahoma this week over its potential responsibility for the opioid crisis in that state, BMO Capital Markets issued a report Thursday on the company's thinking as it heads to court. The Analyst Joanne Wuensch...

Boston Scientific Corporation (NYSE: BSX) delivered a first-quarter miss  in April and adjusted its 2019 guidance. The stock holds several catalysts this year, including the FDA paclitaxel panel, a pipeline update at the company’s analyst meeting in June and the closing of the BTG...

Pharma giant Johnson & Johnson (NYSE: JNJ) hosted a review of its pharmaceutical businesses Wednesday, and analysts came away largely impressed. The Analysts Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with a $145 price target. BMO...

Nevro Corp (NYSE: NVRO) announced a series of board changes and the appointment of a new CEO after the close Tuesday.  The medical device company's stock was surging Wednesday on the news.  The changes at the helm and to the board come in the wake of pressure from Broadfin...

After a 10 percent drop Friday, Johnson & Johnson (NYSE: JNJ) opened Monday’s session down another 2 percent following last week’s Reuters report that the company has known about asbestos contamination in its baby powder for decades. While the potential for legal and regulatory...

Medtech name IRhythm Technologies Inc (NASDAQ: IRTC) is redefining how cardiac arrhythmias are monitored, which makes the stock an attractive buy, according to BMO Capital Markets.  The Analyst BMO analyst Joanne Wuensch initiated coverage of iRhythm Technologies' stock with an...

Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls. The Rating BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price...

With a presence across 10 markets, leadership in some segments and a "robust" product pipeline, Becton Dickinson and Co (NYSE: BDX) is "more than just needles and syringes," according to BMO Capital Markets.  The Analyst BMO analyst Joanne Wuensch initiated coverage...

The medical device company Penumbra Inc (NYSE: PEN) issued a consensus-beating earnings report Nov. 7.  The Analyst BMO Capital Markets' Joanne Wuensch downgraded Penumbra from Outperform to Market Perform and reduced the price target from $117 to $110. The Thesis The analyst said...

Abbott Laboratories (NYSE: ABT) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch upgraded Abbott's stock rating from Market Perform to Outperform with a price target...

BMO Capital Markets has downgraded Endologix, Inc. (NASDAQ: ELGX) to Market Perform from Outperform after FDA’s request of two-year follow-up data from Nellix clinical study, instead of a one-year follow-up. The news sent the company's shares in to a tailspin. The Nellix Issue The Nellix...